Evidence map›Paper›PMID 23626673›Full record

ArticlePloS one2013

Genetic variants associated with increased risk of malignant pleural mesothelioma: a genome-wide association study.

Giuseppe Matullo, Simonetta Guarrera, Marta Betti, Giovanni Fiorito, Daniela Ferrante, Floriana Voglino, Gemma Cadby, Cornelia Di Gaetano, Fabio Rosa, Alessia Russo and 28 more

Erratum issuedOpen access · goldAbstract read
In one paragraph

Article in PloS one, 2013. The graph could read no effect estimate from its abstract, so it casts no vote on the map. An erratum has been issued. Cited by 31 papers.

0numbers the graph read from it
0cells of the map it votes in
31citing papers in PubMed
4.7field-weighted citation impact, top 5% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

31 citing papers in PubMed, 64 citations in OpenAlex.

  1. Article
  2. Article
  3. Review
  4. Article
  5. Article
  6. A study of somaticPleura and peritoneum · 2023
    Article
  7. Article
  8. Article
  9. Article
  10. Review
  11. DNA Methylation ofCancers · 2020
    Article
  12. Review
  13. Article
  14. Article
  15. Review
  16. Review
  17. Article
  18. Article
  19. Frequency of Germline Mutations in Cancer Susceptibility Genes in Malignant Mesothelioma.Journal of clinical oncology : official journal of the American Society of Clinical Oncology · 2018
    Article
  20. Review
4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

38 authors at 15 institutions in 4 countries.

Giuseppe MatulloHuman Genetics Foundation, HuGeF, Turin, Italy. giuseppe.matullo@unito.it
Simonetta Guarrera
Marta Betti
Giovanni Fiorito
Daniela Ferrante
Floriana Voglino
Gemma Cadby
Cornelia Di Gaetano
Fabio Rosa
Alessia Russo
Ari Hirvonen
Elisabetta Casalone
Sara Tunesi
Marina Padoan
Mara Giordano
Anna Aspesi
Caterina Casadio
Francesco Ardissone
Enrico Ruffini
Pier Giacomo Betta
Roberta Libener
Roberto Guaschino
Ezio Piccolini
Monica Neri
Arthur W B Musk
Nicholas H de Klerk
Jennie Hui
John Beilby
Alan L James
Jenette Creaney
Bruce W Robinson
Sutapa Mukherjee
Lyle J Palmer
Dario Mirabelli
Donatella Ugolini
Stefano Bonassi
Corrado Magnani
Irma Dianzani
Università degli Studi del Piemonte Orientale “Amedeo Avogadro” · ITUniversity of Turin · ITItalian institute for Genomic Medicine · ITAzienda Ospedaliera Nazionale SS. Antonio e Biagio e Cesare Arrigo · ITSir Charles Gairdner Hospital · AUUniversity of Western Australia · AUIstituto di Ricovero e Cura a Carattere Scientifico San RaffaeleFinnish Institute of Occupational Health · FILunenfeld-Tanenbaum Research Institute · CAOntario Institute for Cancer Research · CAOspedale di Santo Spirito · ITPathwest Laboratory Medicine · AUPiedmont Reference Center for Epidemiology and Cancer Prevention · ITUniversity of Genoa · ITWomen's College Hospital · CA

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Asbestos exposure is the main risk factor for malignant pleural mesothelioma (MPM), a rare aggressive tumor. Nevertheless, only 5-17% of those exposed to asbestos develop MPM, suggesting the involvement of other environmental and genetic risk factors. To identify the genetic risk factors that may contribute to the development of MPM, we conducted a genome-wide association study (GWAS; 370,000 genotyped SNPs, 5 million imputed SNPs) in Italy, among 407 MPM cases and 389 controls with a complete history of asbestos exposure. A replication study was also undertaken and included 428 MPM cases and 1269 controls from Australia. Although no single marker reached the genome-wide significance threshold, several associations were supported by haplotype-, chromosomal region-, gene- and gene-ontology process-based analyses. Most of these SNPs were located in regions reported to harbor aberrant alterations in mesothelioma (SLC7A14, THRB, CEBP350, ADAMTS2, ETV1, PVT1 and MMP14 genes), causing at most a 2-3-fold increase in MPM risk. The Australian replication study showed significant associations in five of these chromosomal regions (3q26.2, 4q32.1, 7p22.2, 14q11.2, 15q14). Multivariate analysis suggested an independent contribution of 10 genetic variants, with an Area Under the ROC Curve (AUC) of 0.76 when only exposure and covariates were included in the model, and of 0.86 when the genetic component was also included, with a substantial increase of asbestos exposure risk estimation (odds ratio, OR: 45.28, 95% confidence interval, CI: 21.52-95.28). These results showed that genetic risk factors may play an additional role in the development of MPM, and that these should be taken into account to better estimate individual MPM risk in individuals who have been exposed to asbestos.

Indexed as

Genetic LociAgedAsbestosAustraliaCase-Control StudiesFemaleGenetic MarkersGenetic Predisposition to DiseaseGenome-Wide Association StudyHumansItalyMaleMesotheliomaMiddle AgedNeoplasm ProteinsOccupational ExposureAsbestosGenetic MarkersNeoplasm Proteins

Identifiers

PMID23626673
PMCPMC3634031
OpenAlexW2102559580

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.